Company Overview - Yunzhisheng, established in 2012, focuses on IoT artificial intelligence with proprietary intellectual property, initially starting with smart voice technology and later proposing the "cloud-end-chip" architecture to reduce AI deployment costs [1] - The company shifted from consumer hardware to enterprise solutions in 2016 and began its large model transformation journey in 2021, emphasizing the development and application of the "Shanhai Model" [1] - Its products cover smart living (home, automotive, etc.) and smart healthcare, serving over 500 partners [1] IPO Information - IPO date: June 20-25, 2025, with listing on June 30 [2] - Offering price: HKD 165-205 per share, with an entry fee of HKD 4,141.35 (20 shares) [2] - Fundraising amount: Up to HKD 320 million, with a free float of approximately HKD 210 million after cornerstone investors [2] - Green shoe option: 15% over-allotment (234,140 shares), with CICC as the stabilizing agent [2] - Cornerstone investors include SensePower Management Limited and others, accounting for 32.86% [2] - Sponsors: CICC and Haitong [2] - Margin ratio: 22 times [2] Financial Performance - Revenue: 80% from living AI solutions, with the remainder from medical AI solutions, primarily from domestic sources [3] - Living business shows steady growth with a 3-year CAGR of +24%, with key clients including major insurance groups and Shenzhen Metro [3] - AI chip sales increased from 12.8 million in 2022 to 36 million in 2024 [3] - Medical business is the fastest-growing segment with a 3-year CAGR of +32%, increasing client base to 166 in 2024 [3] - Gross margin stable around 40% over three years, slightly declining to 39% in 2024 due to increased procurement costs and lower client retention [4][5] Research and Development - R&D expenditure slightly decreased in 2023 but significantly increased to HKD 370 million in 2024, maintaining a high ratio of 39% [5] - The R&D team comprises 70% of total employees, with a growing reliance on external outsourcing for R&D [5] - The company has accumulated 512 patents and launched the "Shanhai Model" with 60 billion parameters in 2023 [8] Competitive Advantages - As the only unicorn in the AI voice sector, Yunzhisheng has differentiated itself with the "Shanhai Model" and automotive-grade chip technology [7] - The AI solutions market in China is projected to grow at a CAGR of 36.7% from 2024 to 2030 [7] - The company has a diverse product matrix across various sectors, including smart living and healthcare [9] - Customer concentration has decreased, with the largest clients contributing less to total revenue over the years [10] Investment Risks - Financial risks associated with major clients, particularly Shimao Group, which has faced liquidity issues [11] - High accounts receivable and credit risks, with receivables exceeding 50% of total assets [12] - Declining growth in living AI projects and customer retention in the medical sector [13] - Increased competition in the AI market, with a low market share of 0.6% [14] - Continuous operating losses and negative cash flow, raising sustainability concerns [15]

近日，Google Health与DeepMind团队在《Nature》双刊上连发两篇重磅论文，系统发布全新医疗AI模型-AMIE，研究显示，在模拟诊断场景中，AMIE的 整体表现全面超越了初级保健医生，被誉为"对话式医疗AI的里程碑"。 "AI问诊"靠谱吗？人工智能和人的边界到底在哪里？记者采访了数位一线医务工作者和深耕AI+医疗的企业家，他们分享了对于"AI+医疗"的看法和实践 经验。 近日，北京左医科技有限公司（以下简称左医科技）与重庆医科大学附属儿童医院推出24小时在线的儿科"AI家庭医生"，这一产品上线受到了数千位家长 的好评。 左医科技创始人兼CEO张超直言，只有在高质量的临床数据训练下，"AI问诊"才能尽可能做到精准。即便如此，"AI医生"仍然不应具有处方权。 "AI问诊"靠谱吗？ "AI问诊"靠谱吗？将如何影响线下诊疗？在受访的医务工作者中，他们均支持患者使用"AI问诊"，认为"AI问诊"是一种有效的辅助手段。 北京协和医院的孙劲旅教授告诉记者，"对于高年资的医生来说，AI的主要价值在于提高工作效率；而对于年轻医生而言，AI则更多地体现在提升诊疗质 量上。" 张超进一步解释，左医科技从2020 ...

左医科技是业界领先的知识图谱和医疗大模型协同驱动的医疗科技公司。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 2025年将是 AI 应用的爆发之年，这几乎已成为一种共识。 内唯一对标微软Nuance DAX的听译机器人，直接从医患沟通语音中生成病历 ； 2023年5月 ， 左 医科技率先发布医疗垂类大模型，并应用落地与四川省人民医院、北京天坛医院等百强医院，并助力 全国排名前三的儿科医院重庆医科大学附属儿童医院打造行业首个儿科医疗基座大模型。 此外， 左 医科技基于 multi-agent技术打造的AI医生，同宁夏中卫市、银川市、北京西城区卫健委签约，将 AI医生升级为AI家医作为现有家庭医生服务的有效补充。 截至目前， 左医科技打造的 "左手医生"品牌 已成为 国内领先的全科智能医生，提供 AI家庭医生、 智能导诊、预问诊、诊室听译机器人、智能在线问诊等解决方案，通过与不同应用场景的结合，提供 优质的医疗服务，赋能医疗健康行业，现已覆盖200余家三甲医院，其中超过40家为Top100医院。 在发布新一代 AI医疗 产品之际， 左医科技创始人 兼 CEO张超 向「 ...